Sugi Predict

Sugi Predict / Compounds / Isobutyramide

Isobutyramide

Isobutyramide

SCHEMBL189761

C1CCOC1.CC(C)C(N)=O

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.33
▸ EPHX1 P07099 3/20 0.32
▸ LMNA P02545 1/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ CA13 Q8N1Q1 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31
▸ MEN1 O00255 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isobutyramide SCHEMBL8503110 1.00 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2PKMKDM4EEPHX1
Isobutyramide SCHEMBL3983217 0.97 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2PKMKDM4EEPHX1
Dioxane SCHEMBL3231271 0.89 SMN1; SMN2 (0.40) ALDH1A1SMN1; SMN2PKMKDM4EEPHX1
SCHEMBL8882808 0.85 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2PKMKDM4EEPHX1
Isobutyramide SCHEMBL28184607 0.84 EPHX1 (0.32) EPHX1LMNACA12CA1CA2
Tetrahydrofuran SCHEMBL27775685 0.81 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PKMPIK3CDMEN1
Tetrahydrofuran SCHEMBL27268317 0.81 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PKMPIK3CDMEN1
Tetrahydrofuran SCHEMBL913001 0.81 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PKMPIK3CDMEN1
Tetrahydrofuran SCHEMBL27311071 0.80 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2PKMKDM4ELMNA
Tetrahydrofuran SCHEMBL27619217 0.80 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11485925-B2 Lubricous silicone CARDIAC PACEMAKERS, INC. (US) 2022-11-01 — — US claimed
EP-3880265-A1 LUBRICOUS SILICONE Cardiac Pacemakers, Inc. (US) 2021-09-22 — — EP claimed
WO-2020102480-A1 LUBRICOUS SILICONE CARDIAC PACEMAKERS, INC. (US) 2020-05-22 — — WO claimed
US-20200157455-A1 LUBRICOUS SILICONE CARDIAC PACEMAKERS, INC. 2020-05-21 — — US claimed
WO-2013156200-A1 PROCESS FOR PRODUCING (ETHYNE-1,2-DIYL)BIS(ISOBENZOFURAN-1,3- DIONE) NEXAM CHEMICAL AB (SE) 2013-10-24 — — WO claimed
EP-2653467-A1 Process for producing (ethyne-1,2-diyl)bis(isobenzofuran-1,3- dione) Nexam Chemical AB (SE) 2013-10-23 — — EP claimed
EP-2010588-B1 Organosilicon polyurea polymers, elastomers manufactured therefrom and their use HENKEL AG & CO KGAA (DE) 2012-01-04 — — EP claimed
EP-1794158-A2 METHOD FOR PRODUCING TIOTROPIUM SALTS AND SILICON DERIVATIVES AS INTERMEDIATES Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-06-13 — — EP claimed
WO-2006021559-A2 METHOD FOR PRODUCING TIOTROPIUM SALTS AND SILICON DERIVATIVES AS INTERMEDIATES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-03-02 — — WO claimed
US-11485925-B2 Lubricous silicone CARDIAC PACEMAKERS, INC. (US) 2022-11-01 — — US disclosed
EP-3880265-A1 LUBRICOUS SILICONE Cardiac Pacemakers, Inc. (US) 2021-09-22 — — EP disclosed
CN-111902150-A Surface and coating compositions having antifouling, antithrombotic and antibacterial properties and methods of making 乔治亚大学研究基金公司 2020-11-06 — — CN disclosed
WO-2020102480-A1 LUBRICOUS SILICONE CARDIAC PACEMAKERS, INC. (US) 2020-05-22 — — WO disclosed
US-20200157455-A1 LUBRICOUS SILICONE CARDIAC PACEMAKERS, INC. 2020-05-21 — — US disclosed
WO-2006021559-A2 METHOD FOR PRODUCING TIOTROPIUM SALTS AND SILICON DERIVATIVES AS INTERMEDIATES BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-03-02 — — WO disclosed
US-20040127423-A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY 2004-07-01 — — US disclosed
US-20030195157-A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions BRISTOL-MYERS SQUIBB COMPANY 2003-10-16 — — US disclosed
EP-0171410-A1 A BODY TISSUE REPLACEMENT PRODUCT AND A METHOD OF PRODUCING THE PRODUCT MEDINVENT S.A. (CH) 1986-02-19 — — EP disclosed
WO-1985003444-A1 A BODY TISSUE REPLACEMENT PRODUCT AND A METHOD OF PRODUCING THE PRODUCT MEDINVENT S. A. (CH) 1985-08-15 — — WO disclosed
US-4226980-A ANTIBIOTICS, BACTERICIDES ABBOTT LABORATORIES (US) 1980-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195157-A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions GLP1R, IAPP, GIPR ALDH1A1 4854/4885SMN1; SMN2 1408/4885PKM 2080/4885
US-20040127423-A1 Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions GLP1R, IAPP, GIPR ALDH1A1 4854/4885SMN1; SMN2 1408/4885PKM 2080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.